Back Pain News and Research

Latest Back Pain News and Research

iTech Medical receives Health Canada approval for Muscle Pattern Recognition System

iTech Medical, Inc., a medical information technology company, announced today that it has received Health Canada approval for the Company's Muscle Pattern Recognition (MPR) System, a non-invasive clinical assessment tool being developed to assist in the diagnosis and treatment of back and neck pain, one of the most common chronic conditions in Canada.

13 Dec 2010

Excess weight gain during winter holidays increases back injury

Thousands of Americans sustain winter-related back injuries every year, including many injuries directly related to holiday activities. But there are often simple things that can be done to reduce injury risk and minimize or eliminate back pain.

13 Dec 2010

Cesarean-section deliveries may lead to degenerative back disease

Researchers from Michigan State University are studying whether pregnancies, specifically cesarean-section deliveries, are linked to a degenerative back disease that affects women three to nine times more often than men.

13 Dec 2010

New study shows how meditators don't ponder pain

Zen meditation has many health benefits, including a reduced sensitivity to pain. According to new research from the Universit- de Montr-al, meditators do feel pain but they simply don't dwell on it as much. These findings, published in the month's issue of Pain, may have implications for chronic pain sufferers, such as those with arthritis, back pain or cancer.

9 Dec 2010

Ortho Kinematics closes $2 million of new funding

Ortho Kinematics, a privately held spine diagnostics company focused on revolutionizing spine motion analysis announced today the close of $2 million of new funding. TEXO Ventures led the investment, which also included participation by both original investors, PTV Sciences, and Gatebridge Investments.

8 Dec 2010

FDA advisory committee's approval of Contrave for obesity encourages OAC, TOS, ASMBS

The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.

8 Dec 2010

Miracle Applications to sell and market Bioflex Medical Magnetic products

Miracle Applications Corp. is proud to announce it has entered into a Licensing Agreement with Bioflex Medical Magnetic Inc. to sell and market select Bioflex products. The Bioflex magnet is clinically proven to reduce pain, accelerate healing and improve circulation. Bioflex Medical Magnetic Inc. was formed in October, 1986 and BIOflex® Concentric Circle Magnet is the original magnet for human use.

7 Dec 2010

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

7 Dec 2010

Early physical therapy associated with fewer subsequent injections, surgery, physician visits: Study

The American Physical Therapy Association is pointing to a new study on low back pain in Medicare patients in its efforts to encourage the newly established Center for Medicare and Medicaid Innovation to promptly launch a demonstration project on direct access to physical therapist services that was recommended in the recent health reform law.

7 Dec 2010

Thesis reveals stressed young women develop more neck pain than male counterparts

Neck pain is more common in women than men, irrespective of occupation or age. Stressed young women develop more neck pain than their male counterparts. Women also perceive everyday life to be more stressful, reveals a thesis from the University of Gothenburg, Sweden.

7 Dec 2010

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

Independent investigators reported today that patients with paroxysmal nocturnal hemoglobinuria who were treated long-term with Soliris (eculizumab) achieved survival comparable to that of an age- and gender-matched normal population. Findings from this investigator-led analysis were reported in an oral presentation today at the 52nd American Society of Hematology Annual Meeting and Exposition in Orlando.

7 Dec 2010

New analysis evaluates association between hemolysis, mortality in patients with PNH

Alexion Pharmaceuticals, Inc. today announced the presentation of an analysis from the National Data Registry in South Korea that evaluated the association between hemolysis and mortality in patients with paroxysmal nocturnal hemoglobinuria.

7 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

Neurostimulation effective for management of chronic pain

St. Jude Medical, Inc., a global medical device company, today announced two-year results in a post-market clinical study evaluating neurostimulation (spinal cord stimulation) for the management of chronic low back pain. Presented at the 14th annual North American Neuromodulation Society (NANS) meeting in Las Vegas, the study found that 70 percent of neurostimulation patients reported overall pain relief of 50 percent or better at their final two-year visit.

4 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

Physicians prescribe less pain medications for individuals evading the police

If you should find yourself running from the police, watch your step. If you fall and break an ankle, chances are you'll receive less pain medication when they take you to the ER for treatment.

1 Dec 2010

Research reveals tricyclic anti-depressants increase risk of CVD

Research that followed nearly 15,000 people in Scotland has shown that a class of older generation anti-depressant is linked to an increased risk of cardiovascular disease (CVD). The study showed that tricyclic anti-depressants were associated with a 35% increased risk of CVD, but that there was no increased risk with the newer anti-depressants such as the selective serotonin reuptake inhibitors (SSRIs).

1 Dec 2010

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

30 Nov 2010

Prescription rates for controlled medications double for teens, young adults

Adolescents and young adults are most likely to abuse prescription medications. Yet prescription rates for controlled medications, or drugs the Drug Enforcement Administration deems as having the potential for abuse, have nearly doubled for those age groups in the past 14 years, according to a recent study published in Pediatrics. Overall, a controlled medication was prescribed for young adults at approximately one out of every six visits and for young adult by adolescents one out of every nine encounters.

30 Nov 2010

Back Pain News and Research

Latest Back Pain News and Research

iTech Medical receives Health Canada approval for Muscle Pattern Recognition System

Excess weight gain during winter holidays increases back injury

Cesarean-section deliveries may lead to degenerative back disease

New study shows how meditators don't ponder pain

Ortho Kinematics closes $2 million of new funding

FDA advisory committee's approval of Contrave for obesity encourages OAC, TOS, ASMBS

Miracle Applications to sell and market Bioflex Medical Magnetic products

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Early physical therapy associated with fewer subsequent injections, surgery, physician visits: Study

Thesis reveals stressed young women develop more neck pain than male counterparts

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

New analysis evaluates association between hemolysis, mortality in patients with PNH

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Neurostimulation effective for management of chronic pain

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

Physicians prescribe less pain medications for individuals evading the police

Research reveals tricyclic anti-depressants increase risk of CVD

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Prescription rates for controlled medications double for teens, young adults

Innovation in neuroscience drug discovery - eBook eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Back Pain News and Research

Latest Back Pain News and Research

Innovation in neuroscience drug discovery - eBook eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in